TapewireFind a company

organization · Reporting owner

Third Rock Ventures IV, L.P.

Disclosed activity across 7 companies

Tapewire entity
73568
SEC CIK
0001688327

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Fulcrum Therapeutics, Inc.FULC · Entity 596910% ownerJuly 22, 2019July 22, 2019
Maze Therapeutics, Inc.MAZE · Entity 177510% ownerNovember 04, 2025November 05, 2025
PLIANT THERAPEUTICS, INC.PLRX · Entity 702210% ownerJune 05, 2020June 09, 2020
Relay Therapeutics, Inc.RLAY · Entity 404410% ownerJanuary 12, 2021January 14, 2021
Revolution Medicines, Inc.RVMD · Entity 60610% ownerFebruary 18, 2020February 18, 2020
Tango Therapeutics, Inc.TNGX · Entity 149710% ownerOctober 23, 2025October 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fulcrum Therapeutics, Inc.

Report date July 22, 2019 · Filed July 22, 2019

Jointly reported with Third Rock Ventures GP IV, L.P., TRV GP IV, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,343,154 Last balance in matching sequence After 2019-07-22 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2019-07-22 · Conversion · Acquired 2,261,904 · Balance 2,261,904

F1: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Row 2 · 2019-07-22 · Purchase · Acquired 81,250 · Balance 2,343,154

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-07-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2019-07-22 · Conversion · Disposed 15,833,333 · Balance 0

F1: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect4,473,958 Reported balance After 2025-11-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-11-04 · Other · Disposed 1,600,000 · Balance 4,473,958

F1: On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes950,800 Reported balance Holding disclosure · report date 2025-11-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 950,800

F3: The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F3: The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,839,160 Reported balance After 2020-06-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-06-05 · Conversion · Acquired 5,559,440 · Balance 5,839,160

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3: These shares are directly held by TRV III.

F4: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes2,132,867 Reported balance After 2020-06-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-06-05 · Conversion · Acquired 2,132,867 · Balance 2,132,867

F5: Represents the total number of shares of Common Stock received by Third Rock Ventures IV, L.P. ("TRV IV") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F6: These shares are directly held by Third Rock Ventures IV.

F7: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-06-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-06-05 · Conversion · Disposed 39,750,000 · Balance 0

F2: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3: These shares are directly held by TRV III.

F4: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnotes0 Reported balance After 2020-06-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-06-05 · Conversion · Disposed 15,250,000 · Balance 0

F2: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F6: These shares are directly held by Third Rock Ventures IV.

F7: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3: These shares are directly held by TRV III.

F4: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F5: Represents the total number of shares of Common Stock received by Third Rock Ventures IV, L.P. ("TRV IV") upon conversion of the preferred stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F6: These shares are directly held by Third Rock Ventures IV.

F7: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F8: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,739,918 Last balance in matching sequence After 2021-01-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2021-01-12 · Sale · Disposed 1,500,000 · Balance 9,051,115

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 2 · 2021-01-13 · Sale · Disposed 1,247,873 · Balance 7,803,242

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 3 · 2021-01-13 · Sale · Disposed 8,727 · Balance 7,794,515

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 4 · 2021-01-13 · Sale · Disposed 42,860 · Balance 7,751,655

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 5 · 2021-01-13 · Sale · Disposed 4,325 · Balance 7,747,330

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 6 · 2021-01-13 · Sale · Disposed 7,412 · Balance 7,739,918

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes0 Last balance in matching sequence After 2021-01-14 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 7 · 2021-01-13 · Sale · Disposed 805,050 · Balance 2,006,147

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 8 · 2021-01-13 · Sale · Disposed 5,630 · Balance 2,000,517

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 9 · 2021-01-13 · Sale · Disposed 27,650 · Balance 1,972,867

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 10 · 2021-01-13 · Sale · Disposed 2,791 · Balance 1,970,076

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 11 · 2021-01-13 · Sale · Disposed 4,782 · Balance 1,965,294

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 12 · 2021-01-14 · Sale · Disposed 1,965,294 · Balance 0

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Revolution Medicines, Inc.

Report date February 18, 2020 · Filed February 18, 2020

Jointly reported with Third Rock Ventures GP IV, L.P., TRV GP IV, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,419,900 Reported balance After 2020-02-18 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-02-18 · Conversion · Acquired 1,419,900 · Balance 1,419,900

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures IV, L.P. ("TRV IV") upon conversion of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-02-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-02-18 · Conversion · Disposed 1,027,516 · Balance 0

F2: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-02-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-02-18 · Conversion · Disposed 342,505 · Balance 0

F2: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-02-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-02-18 · Conversion · Disposed 49,879 · Balance 0

F2: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock received by Third Rock Ventures IV, L.P. ("TRV IV") upon conversion of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Tango Therapeutics, Inc.

Report date October 23, 2025 · Filed October 27, 2025

Jointly reported with Third Rock Ventures GP IV, L.P., TRV GP IV, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect13,386,574 Reported balance After 2025-10-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-10-23 · Sale · Disposed 477,401 · Balance 13,386,574

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dianthus Therapeutics, Inc. /DE/

Report date February 07, 2023 · Filed February 09, 2023

Jointly reported with Third Rock Ventures GP IV, L.P., TRV GP IV, LLC

Section 16 reporting ended · disclosed 2023-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,058,204 Last balance in matching sequence After 2023-02-08 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2023-02-07 · Sale · Disposed 2,200,000 · Balance 4,558,204

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Row 2 · 2023-02-08 · Sale · Disposed 1,500,000 · Balance 3,058,204

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 04, 2025 Filed Nov 5, 2025 21:15 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 OtherCommon Stock 1,600,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-266981 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,473,958

F1 · kind: On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
October 23, 2025 Filed Oct 27, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 477,401 $10.15 $4,846,574.95
Disclosure

SEC source: 0001193125-25-251606 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,386,574

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
September 25, 2025 Filed Sep 29, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 500,000 $8.02 $4,008,500.00
Disclosure

SEC source: 0001193125-25-223227 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,863,975

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
September 16, 2025 Filed Sep 17, 2025 22:06 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 363,541 $7.04 $2,559,328.64
Disclosure

SEC source: 0001193125-25-206453 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,363,975

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 86,459 $7.04 $608,628.13
Disclosure

SEC source: 0001193125-25-199177 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,727,516

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
September 05, 2025 Filed Sep 9, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 642,906 $7.00 $4,500,342.00
Disclosure

SEC source: 0001193125-25-199177 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,813,975

F1 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 22, 2025 Filed Aug 26, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 302,194 $7.00 $2,115,358.00
Disclosure

SEC source: 0000950170-25-111457 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,456,881

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 19, 2025 Filed Aug 21, 2025 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 1,100,000 $7.01 $7,712,760.00
Disclosure

SEC source: 0000950170-25-110662 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,759,075

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:31 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionSeries A Preferred Stock · Derivative 9,166,666 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013760 · ownership.xml · derivative · entry 5

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 950,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.nature: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:31 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionSeries D-1 Preferred Stock · Derivative 9,725,709 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013760 · ownership.xml · derivative · entry 4

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,008,786 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: The shares are held directly by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:31 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionSeries A Preferred Stock · Derivative 45,833,334 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013760 · ownership.xml · derivative · entry 3

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,754,002 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: The shares are held directly by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:31 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionCommon Stock 950,800 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013760 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 950,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.nature: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 22:31 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionCommon Stock 5,762,788 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013760 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Third Rock Ventures V, L.P. · CIK 0001778071 · 10% owner

Third Rock Ventures GP V, LP · CIK 0001977498 · 10% owner

TRV GP V, LLC · CIK 0001990717 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,073,958

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series D-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-0.1037 basis without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: The shares are held directly by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4 · ownership.direct: Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:48 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 67,400 $10.53 $709,755.70
Disclosure

SEC source: 0000950170-24-107330 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,859,075

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
September 05, 2024 Filed Sep 9, 2024 23:19 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 75,000 $11.56 $867,135.00
Disclosure

SEC source: 0000950170-24-104863 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,926,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.54 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 30, 2024 Filed Sep 5, 2024 00:42 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 175,000 $11.60 $2,029,702.50
Disclosure

SEC source: 0000950170-24-103661 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,001,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.52 to $11.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 27, 2024 Filed Aug 29, 2024 20:40 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 25,000 $11.55 $288,665.00
Disclosure

SEC source: 0000950170-24-101910 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,176,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.53 to $11.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 19, 2024 Filed Aug 20, 2024 21:59 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 150,000 $10.09 $1,513,920.00
Disclosure

SEC source: 0000950170-24-099253 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,201,475

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 21:59 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 135,000 $9.79 $1,321,447.50
Disclosure

SEC source: 0000950170-24-099253 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,351,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 01, 2024 Filed Aug 1, 2024 21:51 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 40,000 $9.80 $392,000.00
Disclosure

SEC source: 0000950170-24-089474 · ownership.xml · nonDerivative · entry 3

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,486,475

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 31, 2024 Filed Aug 1, 2024 21:51 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 100,000 $9.93 $993,380.00
Disclosure

SEC source: 0000950170-24-089474 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,526,475

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.84 to $10.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 30, 2024 Filed Aug 1, 2024 21:51 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 95,000 $9.80 $931,114.00
Disclosure

SEC source: 0000950170-24-089474 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,626,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $9.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 26, 2024 Filed Jul 30, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 50,000 $9.84 $491,950.00
Disclosure

SEC source: 0000950170-24-087862 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,721,475

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 25, 2024 Filed Jul 26, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 100,599 $9.87 $992,771.29
Disclosure

SEC source: 0000950170-24-086894 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,771,475

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.005, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 200,000 $9.82 $1,963,160.00
Disclosure

SEC source: 0000950170-24-086894 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,872,074

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.78 to $10.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 23, 2024 Filed Jul 24, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 125,000 $9.79 $1,223,350.00
Disclosure

SEC source: 0000950170-24-086051 · ownership.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,072,074

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 262,740 $9.78 $2,570,096.41
Disclosure

SEC source: 0000950170-24-086051 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,197,074

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 18, 2024 Filed Jul 22, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 191,490 $9.81 $1,878,478.60
Disclosure

SEC source: 0000950170-24-085256 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,459,814

F1 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
July 17, 2024 Filed Jul 18, 2024 20:15 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 550,171 $9.79 $5,386,339.14
Disclosure

SEC source: 0000950170-24-084580 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,651,304

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
February 20, 2024 Filed Feb 21, 2024 22:52 UTC Tango Therapeutics, Inc. TNGX · Entity 1497 SaleCommon Stock 162,500 $12.00 $1,950,000.00
Disclosure

SEC source: 0000950170-24-018198 · ownership.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,201,475

F1 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:30 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 1,500,000 $0.82 $1,230,000.00
Disclosure

SEC source: 0000899243-23-004411 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,058,204

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 21:30 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 2,200,000 $0.83 $1,826,000.00
Disclosure

SEC source: 0000899243-23-004411 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,558,204

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
August 25, 2021 Filed Aug 26, 2021 21:54 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 OtherCommon Stock 1,250,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-034297 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,758,204

F1 · kind: On August 25, 2021, Third Rock Ventures IV, L.P. ("TRV IV") distributed for no consideration, 1,250,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV"), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On August 25, 2021, Third Rock Ventures IV, L.P. ("TRV IV") distributed for no consideration, 1,250,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV"), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Read SEC document
January 14, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,965,294 $41.00 $80,577,054.00
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 12

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 4,782 $44.73 $213,898.86
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 11

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,965,294

F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 2,791 $44.00 $122,804.00
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 10

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,970,076

F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 27,650 $42.12 $1,164,618.00
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 9

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,972,867

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 5,630 $41.08 $231,280.40
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 8

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,000,517

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 805,050 $40.01 $32,210,050.50
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 7

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,006,147

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 7,412 $44.73 $331,538.76
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 6

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,739,918

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 4,325 $44.00 $190,300.00
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 5

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,747,330

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 42,860 $42.12 $1,805,263.20
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,751,655

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 8,727 $41.08 $358,505.16
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 3

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,794,515

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 13, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,247,873 $40.01 $49,927,398.73
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,803,242

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 20:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,500,000 $40.00 $60,000,000.00
Disclosure

SEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,051,115

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionSeries B Convertible Preferred Stock · Derivative 61,881 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · derivative · entry 8

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 17,427 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F4 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV").

F5 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F6 · ownership.nature: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F7 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionSeries B Convertible Preferred Stock · Derivative 61,881 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · derivative · entry 7

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,427 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F6 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III").

F2 · ownership.direct: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of the reporting persons, except for TRV III, disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F6 · ownership.direct: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F7 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionSeries A Convertible Preferred Stock · Derivative 9,920,455 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · derivative · entry 6

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,793,770 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · ownership.nature: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F4 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV").

F5 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F7 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionSeries A Convertible Preferred Stock · Derivative 35,404,286 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · derivative · entry 5

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,970,454 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III").

F2 · ownership.direct: The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of the reporting persons, except for TRV III, disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3 · ownership.direct: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F7 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document
July 20, 2020 Filed Jul 21, 2020 19:23 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 ConversionCommon Stock 17,427 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-019850 · doc4.xml · nonDerivative · entry 4

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner

Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner

TRV GP IV, LLC · CIK 0001688325 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,811,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV").

F5 · ownership.nature: The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F6 · ownership.nature: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.

F7 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.